Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Class A Common Stock, $0.001 par value per share
-
Shares outstanding
-
58.8M
-
Number of holders
-
48
-
Total 13F shares, excl. options
-
17.3M
-
Shares change
-
+5.45M
-
Total reported value, excl. options
-
$176M
-
Value change
-
+$56M
-
Number of buys
-
39
-
Number of sells
-
-12
-
Price
-
$10.14
Significant Holders of Immuneering Corp - Class A Common Stock, $0.001 par value per share (IMRX) as of Q2 2023
54 filings reported holding IMRX - Immuneering Corp - Class A Common Stock, $0.001 par value per share as of Q2 2023.
Immuneering Corp - Class A Common Stock, $0.001 par value per share (IMRX) has 48 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17.3M shares
of 58.8M outstanding shares and own 29.39% of the company stock.
Largest 10 shareholders include Cormorant Asset Management, LP (4.2M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.58M shares), BlackRock Inc. (2.42M shares), CITADEL ADVISORS LLC (2.07M shares), VANGUARD GROUP INC (1M shares), BANK OF MONTREAL /CAN/ (714K shares), FMR LLC (658K shares), GOLDMAN SACHS GROUP INC (489K shares), GEODE CAPITAL MANAGEMENT, LLC (388K shares), and STATE STREET CORP (334K shares).
This table shows the top 48 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.